Background Clostridium difficile is a leading cause of morbidity and mortality in several
countries. However, there are limited evidence characterizing its role as a global public …

AIM To perform a systematic review and meta-analysis on proton pump inhibitors (PPIs)
therapy and the risk of Clostridium difficile infection (CDI). METHODS We conducted a …

Triptolide (TP), a traditional Chinese medicine, has been reported to be effective in the
treatment of autoimmune diseases and exerting antineoplastic activity in several human …

Objective: To provide an update to the “Surviving Sepsis Campaign Guidelines for
Management of Severe Sepsis and Septic Shock,” last published in 2008. Design: A …

Proton pump inhibitors (PPIs) marked a before and after in the management of gastric acid‐
related disorders since their introduction to the market in 1989. Due to a novel, highly …

Background Clostridium difficile infection is the leading cause of health care–associated
diarrhea, and the bacterium can also be carried asymptomatically. The objective of this study …

OBJECTIVES: Several studies have raised concern regarding the possible association
between proton-pump inhibitors (PPIs) andClostridium difficileinfection (CDI). We aimed to …

Aliment Pharmacol Ther 2011; 34: 1269–1281 Summary Background The use of proton
pump inhibitors (PPIs) is increasing worldwide. Suppression of gastric acid alters the …

OBJECTIVES: Clostridium difficile-associated diarrhea (CDAD) is a major cause of morbidity
and increasing health-care costs among hospitalized patients. Although exposure to …

Background: The reported risk of hypomagnesemia in patients with proton pump inhibitor
(PPI) use is conflicting. The objective of this meta-analysis was to assess the association …